<DOC>
	<DOCNO>NCT02959164</DOCNO>
	<brief_summary>The purpose Phase 1b study assess safety maximum tolerate dose ( MTD ) Decitabine combination Gemcitabine among previously treat patient diagnose advanced pancreatic adenocarcinoma sarcoma ( soft tissue bone ) .</brief_summary>
	<brief_title>Decitabine Gemcitabine Pancreatic Cancer Sarcoma</brief_title>
	<detailed_description>The objective study assess safety tolerability combination Decitabine Gemcitabine previously treat patient advanced pancreatic cancer advance sarcoma define recommend Phase II dose describe dose-limiting toxicity combination Decitabine Gemcitabine . The preliminary efficacy parameter combination Decitabine Gemcitabine estimate term response rate disease control rate progression-free survival .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Patients must metastatic histologically cytologically confirm pancreatic adenocarcinoma sarcoma ( soft tissue bone ) progression document least one line therapy . 2 . Age ≥18 year . 3 . ECOG performance status ≤2 ( Karnofsky ≥60 % ( See Appendix 1 ) . 4 . Life expectancy great 3 month . 5 . Measureable disease per RECIST criterion . 6 . Patients must normal organ marrow function define : Absolute neutrophil count ≥1,500/mm3 Platelets ≥100 k/mm3 Total bilirubin within normal institutional limit AST ( SGOT ) /ALT ( SGPT ) ≤2.5 × institutional upper limit normal Creatinine within normal institutional limit OR Creatinine clearance ≥60 mL/min/1.73 m2 patient creatinine level institutional normal . 7 . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) time consent duration study participation well 3 month completion study drug . Adequate contraception consist double method contraception , one method must barrier method . WOCBP define sexually mature woman undergone hysterectomy naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) . If woman ( male subject 's female partner ) become pregnant suspect pregnant participate study , inform treat physician immediately . 8 . Ability understand willingness sign write informed consent document . 1 . Chemotherapy radiotherapy within 4 week ( targeted therapy 5 halflives ) prior enter study failure recover adverse event due agent administer &lt; /= grade 1 stable grade 2 , discretion treat physician . 2 . Patients receive investigational agent . 3 . Known brain metastasis . 4 . History allergic reaction attribute compound similar chemical biologic composition Decitabine agent use study . 5 . Prior Decitabine treatment cancer . Patients previous exposure therapy Gemcitabine allow study . 6 . Pregnant breast feed woman exclude participate study . WOCBP must negative serum pregnancy test within 7 day first administration Decitabine . 7 . Patients know positivity human immunodeficiency virus ( HIV ) hepatitis C ; baseline test HIV hepatitis C require . 8 . Patients significant history noncompliance medical regimen inability grant reliable informed consent . 9 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>